Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response
- PMID: 38132455
- PMCID: PMC10742411
- DOI: 10.3390/cimb45120609
Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response
Abstract
Malignant tumors exhibit rapid growth and high metabolic rates, similar to embryonic stem cells, and depend on aerobic glycolysis, known as the "Warburg effect". This understanding has enabled the use of radiolabeled glucose analogs in tumor staging and therapeutic response assessment via PET scans. Traditional treatments like chemotherapy and radiotherapy target rapidly dividing cells, causing significant toxicity. Despite immunotherapy's impact on solid tumor treatment, gaps remain, leading to research on cancer cell evasion of immune response and immune tolerance induction via interactions with the tumor microenvironment (TME). The TME, consisting of immune cells, fibroblasts, vessels, and the extracellular matrix, regulates tumor progression and therapy responses. TME-targeted therapies aim to transform this environment from supporting tumor growth to impeding it and fostering an effective immune response. This review examines the metabolic disparities between immune cells and cancer cells, their impact on immune function and therapeutic targeting, the TME components, and the complex interplay between cancer cells and nontumoral cells. The success of TME-targeted therapies highlights their potential to achieve better cancer control or even a cure.
Keywords: immunotherapy; oncometabolites; tumor microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.OMICS. 2020 Apr;24(4):175-179. doi: 10.1089/omi.2020.0019. Epub 2020 Mar 13. OMICS. 2020. PMID: 32176591 Review.
-
Unlocking the potential of the tumor microenvironment for cancer therapy.Pathol Res Pract. 2023 Nov;251:154846. doi: 10.1016/j.prp.2023.154846. Epub 2023 Oct 4. Pathol Res Pract. 2023. PMID: 37837860 Review.
-
Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.Front Endocrinol (Lausanne). 2022 Aug 15;13:988295. doi: 10.3389/fendo.2022.988295. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36046791 Free PMC article. Review.
-
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.Biomark Res. 2024 Sep 3;12(1):96. doi: 10.1186/s40364-024-00646-1. Biomark Res. 2024. PMID: 39227970 Free PMC article. Review.
-
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.Cell Oncol (Dordr). 2021 Dec;44(6):1209-1229. doi: 10.1007/s13402-021-00634-9. Epub 2021 Sep 16. Cell Oncol (Dordr). 2021. PMID: 34528143 Review.
Cited by
-
Editorial: Targeting nucleotide metabolism for enhancing antitumor immunity.Front Immunol. 2024 Apr 23;15:1412057. doi: 10.3389/fimmu.2024.1412057. eCollection 2024. Front Immunol. 2024. PMID: 38715612 Free PMC article. No abstract available.
-
A cuproptosis-related gene DLAT as a novel prognostic marker and its relevance to immune infiltration in low-grade gliomas.Heliyon. 2024 Jun 6;10(11):e32270. doi: 10.1016/j.heliyon.2024.e32270. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38961981 Free PMC article.
-
Single-cell analysis identifies distinct macrophage phenotypes associated with prodisease and proresolving functions in the endometriotic niche.Proc Natl Acad Sci U S A. 2024 Sep 17;121(38):e2405474121. doi: 10.1073/pnas.2405474121. Epub 2024 Sep 10. Proc Natl Acad Sci U S A. 2024. PMID: 39255000 Free PMC article.
-
Improving tumor microenvironment assessment in chip systems through next-generation technology integration.Front Bioeng Biotechnol. 2024 Sep 25;12:1462293. doi: 10.3389/fbioe.2024.1462293. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39386043 Free PMC article. Review.
-
N6-Methyladenosine methylation modification in breast cancer: current insights.J Transl Med. 2024 Oct 28;22(1):971. doi: 10.1186/s12967-024-05771-x. J Transl Med. 2024. PMID: 39468547 Free PMC article. Review.
References
-
- Walcher L., Kistenmacher A.K., Suo H., Kitte R., Dluczek S., Strauß A., Blaudszun A.R., Yevsa T., Fricke S., Kossatz-Boehlert U. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front. Immunol. 2020;11:1280. doi: 10.3389/fimmu.2020.01280. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources